Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis

BACKGROUND: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to the beta-emitters such as Lutetium...

Descripción completa

Detalles Bibliográficos
Autores principales: Parida, Girish Kumar, Panda, Raj Abhisek, Bishnoi, Komal, Agrawal, Kanhaiyalal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601660/
https://www.ncbi.nlm.nih.gov/pubmed/37247612
http://dx.doi.org/10.1159/000531246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601660/
https://www.ncbi.nlm.nih.gov/pubmed/37247612
http://dx.doi.org/10.1159/000531246

Ejemplares similares